Axonics

Executive Summary

Axonics, now a wholly-owned subsidiary of Boston Scientific following its acquisition in 2024, is a leader in sacral neuromodulation (SNM) therapy for urinary and bowel dysfunction. Its flagship miniaturized, rechargeable neurostimulator offers enhanced patient comfort and convenience compared to legacy devices, driving adoption in the overactive bladder and fecal incontinence markets. As part of Boston Scientific, Axonics benefits from the parent company's global commercial infrastructure and R&D resources, enabling accelerated market penetration and next-generation product development. The company's strong clinical evidence and differentiated technology position it well within the growing neuromodulation space, though integration execution and competition from Medtronic remain key considerations. Overall, Axonics represents a strategically valuable asset with steady growth prospects, supported by expanding indications and geographic reach.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of next-generation rechargeable SNM system80% success
• Q3 2026Publication of 5-year clinical outcomes for overactive bladder90% success
• TBDExpanded Medicare reimbursement coverage for SNM in fecal incontinence60% success